What the MCCQE tests in endocrinology
Endocrinology on the MCCQE is mostly diabetes, thyroid, calcium and bone, with smaller numbers of adrenal and pituitary questions. The exam wants a safe generalist: someone who can diagnose diabetes correctly, choose the next drug using Canadian guidance, manage a diabetic emergency in the first hours, interpret a thyroid panel without over-testing, and know when an endocrine problem needs urgent action.
Across the dimensions of care, acute questions cover DKA, hyperosmolar hyperglycemic state, severe hypoglycemia, adrenal crisis, thyroid storm and symptomatic hypercalcemia. Chronic care covers type 2 diabetes intensification, complication screening, hypothyroidism, osteoporosis and obesity. Health promotion covers diabetes screening, fracture risk assessment and weight management. Psychosocial items include cost of medications, driving with diabetes, and shared decisions about insulin.
Many endocrine stems are lab-based. Expect a short history followed by values in SI units: glucose in mmol/L, A1C as a percentage, calcium in mmol/L, TSH in mU/L, free T4 in pmol/L, creatinine in micromoles per litre. The lead-in is often "most appropriate next investigation" or "most appropriate change in therapy".
- Acute: DKA, HHS, hypoglycemia, adrenal crisis, thyroid storm, severe hypercalcemia
- Chronic: type 2 diabetes intensification, hypothyroidism, osteoporosis, obesity
- Prevention: diabetes screening, complication screening, fracture risk assessment
- Communication: sick-day rules, hypoglycemia and driving, informed choice about therapy
Diabetes: diagnosis, targets and drug choice
Diabetes Canada diagnoses diabetes with a fasting plasma glucose of 7.0 mmol/L or more, an A1C of 6.5% or more in adults, a 2-hour plasma glucose of 11.1 mmol/L or more on a 75 g oral glucose tolerance test, or a random glucose of 11.1 mmol/L or more with classic symptoms. Without symptoms, a second abnormal test is needed to confirm. Screening is suggested every 3 years from age 40, and earlier or more often in people at high risk.
The usual A1C target is 7.0% or less, individualised: tighter for some younger, healthy patients, and looser in frail older adults or those with frequent hypoglycemia. Blood pressure, lipids and lifestyle are as important as glucose for outcomes.
Drug choice is where the MCCQE tests Canadian guidance. Start healthy behaviour interventions and metformin for most people. If the A1C is 1.5% or more above target at diagnosis, consider starting metformin with a second agent. If the patient has symptomatic hyperglycemia with metabolic decompensation, start insulin. In a patient with established atherosclerotic cardiovascular disease, heart failure or chronic kidney disease, add an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiorenal benefit, and Diabetes Canada recommends doing this for those conditions regardless of the current A1C. Choose the class to match the problem: SGLT2 inhibitors for heart failure and CKD, GLP-1 receptor agonists when weight loss and atherosclerotic risk dominate.
Complication screening is a frequent short question. People with type 2 diabetes need yearly kidney screening with eGFR and urine albumin to creatinine ratio, retinopathy screening by an eye care professional, and foot examination for neuropathy and ulcers. Statins are recommended for most adults with diabetes aged 40 or older, and an ACE inhibitor or ARB is chosen for those with albuminuria or cardiovascular disease.
Counselling items: sick-day medication rules, driving safety, and pregnancy planning. Diabetes Canada sick-day advice tells patients to hold certain drugs during dehydrating illness (often taught with the mnemonic SADMANS: sulfonylureas, ACE inhibitors, diuretics, metformin, ARBs, NSAIDs, SGLT2 inhibitors). Patients on insulin or insulin secretagogues should check glucose before driving and not drive if it is below 5.0 mmol/L.
- Diagnosis needs two abnormal tests unless symptoms are clear
- A1C 1.5% or more above target: consider metformin plus a second agent
- ASCVD, heart failure or CKD: add an agent with proven cardiorenal benefit, independent of A1C
- SGLT2 inhibitors can cause euglycemic DKA; hold them during acute illness and before surgery
Type 1 diabetes, insulin and hypoglycemia safety
Type 1 diabetes questions test basic insulin logic. People with type 1 diabetes always need basal insulin, even when they are not eating, because without it they make ketones. Basal-bolus therapy (a long-acting insulin plus rapid-acting insulin with meals) or an insulin pump is the usual regimen. The most common error the exam looks for is stopping all insulin during vomiting or fasting; the correct advice is to keep the basal insulin, check glucose and ketones more often, keep drinking fluids and seek care if ketones rise or vomiting persists.
Adults who seem to have type 2 diabetes but are lean, lose weight quickly or fail oral agents early may have latent autoimmune diabetes. Islet autoantibodies and a low C-peptide support the diagnosis, and these patients need insulin sooner. A young person with mild stable hyperglycemia and a strong family history over several generations raises the possibility of monogenic diabetes, which is a referral question rather than a management one.
Hypoglycemia unawareness develops after repeated lows and long-standing diabetes. The patient loses the warning symptoms (sweating, tremor, palpitations) and goes straight to confusion. Management is to find the cause, relax glucose targets for a period, consider continuous glucose monitoring and review driving safety. Glucagon should be prescribed for people at risk of severe hypoglycemia, and family members should know how to give it.
Insulin initiation in type 2 diabetes is a counselling question as much as a drug question. A common start is a single dose of basal insulin at bedtime, titrated by the patient using fasting glucose readings. Explain how to recognise and treat hypoglycemia, how to adjust the dose, and that insulin is a normal step in a progressive disease, not a personal failure.
- Type 1 diabetes: never stop basal insulin, even when not eating
- Lean adult failing oral agents: think latent autoimmune diabetes
- Hypoglycemia unawareness: relax targets, consider CGM, review driving
- Prescribe glucagon for patients at risk of severe lows
Diabetic emergencies: DKA, HHS and hypoglycemia
DKA questions test the order of treatment. First, IV fluid with 0.9% sodium chloride to restore volume. Next, check the potassium before insulin: if it is low, replace potassium first and hold insulin, because insulin drives potassium into cells and can cause a dangerous drop. Once potassium is adequate, start a continuous IV insulin infusion. When glucose falls, add dextrose to the fluids and continue insulin until the anion gap closes; the gap, not the glucose, tells you when to stop. Bicarbonate is reserved for very severe acidosis. Always look for the trigger: infection, missed insulin, myocardial infarction, new diagnosis, or an SGLT2 inhibitor.
Euglycemic DKA is a modern trap. A patient with type 2 diabetes on an SGLT2 inhibitor may present with nausea, abdominal pain and a high anion gap acidosis with a glucose that looks only mildly raised. Check ketones and the blood gas, and stop the drug.
HHS presents in older adults with type 2 diabetes, often with infection, profound dehydration, very high glucose, high serum osmolality and altered consciousness, with little ketosis. Fluids are the main treatment. Correct glucose and sodium gradually, because rapid shifts in osmolality can cause cerebral edema.
Hypoglycemia is a glucose below 4.0 mmol/L in a person on insulin or a secretagogue. A conscious patient takes 15 g of fast-acting carbohydrate and rechecks in 15 minutes; a patient who cannot swallow needs glucagon or IV dextrose. In a person without diabetes, document Whipple triad, then test insulin, C-peptide and a sulfonylurea screen during an episode. High insulin with low C-peptide suggests exogenous insulin; high insulin with high C-peptide suggests an insulinoma or a secretagogue.
- DKA order: fluids, check potassium, then insulin, add dextrose as glucose falls
- Stop insulin infusion only when the anion gap is closed and subcutaneous insulin overlaps
- Sulfonylurea hypoglycemia can recur for many hours: admit and observe
DKA management in the right order
- 1Confirm DKA and find the triggerGlucose, gas, anion gap, ketones, electrolytes. Look for infection, missed insulin, MI, new diabetes or an SGLT2 inhibitor.
- 2Start IV fluids0.9% sodium chloride to restore circulating volume, then continue at a rate guided by hydration and sodium.
- 3Check potassium before insulinIf potassium is low, replace it and hold insulin until it is safe. Add potassium to fluids as levels fall.
- 4Start an IV insulin infusionContinuous insulin to switch off ketone production. Bicarbonate only for very severe acidosis.
- 5Add dextrose as glucose fallsKeep insulin running while giving dextrose, because the acidosis, not the glucose, is the target.
- 6Close the gap, then overlapStop the infusion only when the anion gap has closed and subcutaneous insulin has been given with overlap.
Thyroid, adrenal and pituitary decision points
TSH is the first test for suspected thyroid disease in an outpatient. Order free T4 when TSH is abnormal, and avoid routine T3. Choosing Wisely Canada recommends against ordering a full thyroid panel as a screening test and against thyroid ultrasound for routine hypothyroidism. Primary hypothyroidism (high TSH, low free T4) is treated with levothyroxine, started at a low dose in older adults and those with coronary disease.
For hyperthyroidism (low TSH, high free T4 or T3), find the cause before choosing treatment. A radionuclide uptake scan separates Graves disease (diffuse high uptake) and toxic nodules (focal uptake) from thyroiditis (low uptake). Beta-blockers treat symptoms. Thyroiditis, including postpartum thyroiditis, is managed supportively because antithyroid drugs do not help. Methimazole is the usual antithyroid drug; propylthiouracil is preferred in the first trimester of pregnancy.
Thyroid nodules start with TSH and ultrasound. If TSH is low, a radionuclide scan comes next: a hot nodule is rarely malignant and is not biopsied first. If TSH is normal or high, ultrasound features and size decide whether fine-needle aspiration is needed.
Adrenal crisis presents with hypotension unresponsive to fluids, vomiting, abdominal pain, hyponatremia and hyperkalemia, often in a patient on long-term steroids who stopped them. Draw cortisol and ACTH if this does not delay care, then give IV hydrocortisone and fluids without waiting for results. For suspected Cushing syndrome, screen with an overnight dexamethasone suppression test, late-night salivary cortisol or 24-hour urine free cortisol. Screen for primary aldosteronism with an aldosterone to renin ratio in hypertension with hypokalemia, resistant hypertension or an adrenal incidentaloma, in line with Hypertension Canada. Screen for pheochromocytoma with plasma or urine metanephrines, and never biopsy an adrenal mass before excluding it.
Pituitary questions focus on prolactin and mass effect. Before calling raised prolactin a prolactinoma, exclude pregnancy, hypothyroidism, renal failure and drugs such as antipsychotics. A dopamine agonist is first-line even for most macroprolactinomas. Sudden headache, visual loss and hypotension in a patient with a pituitary mass suggest apoplexy: give stress-dose steroids and arrange urgent imaging and neurosurgery.
- TSH first, free T4 second, T3 rarely
- Low TSH with a nodule: scan before biopsy
- Adrenal crisis: give hydrocortisone first, confirm later
- Adrenal mass: exclude pheochromocytoma before any biopsy or surgery
Endocrine red flags that need action now
Calcium, osteoporosis and obesity
For hypercalcemia, correct for albumin or check ionized calcium, then measure PTH. A high or inappropriately normal PTH means primary hyperparathyroidism, usually in an outpatient with mild symptoms. A suppressed PTH points to malignancy (PTHrP, bone metastases, myeloma), vitamin D excess, granulomatous disease or drugs such as thiazides and lithium. Severe symptomatic hypercalcemia is treated with IV normal saline first, then an IV bisphosphonate; calcitonin works faster but briefly. Hypocalcemia after thyroid or parathyroid surgery, with perioral tingling, Chvostek or Trousseau signs or a long QT, needs IV calcium gluconate.
Osteoporosis Canada's current guideline suggests fracture risk assessment and BMD testing in postmenopausal females and males aged 70 and older, at 65 to 69 with one clinical risk factor, and at 50 to 64 with a prior fragility fracture or two or more risk factors. Fracture risk is estimated with FRAX. A hip or vertebral fragility fracture is itself an indication to consider treatment. Bisphosphonates (alendronate, risedronate, zoledronic acid) are first-line; menopausal hormone therapy is an option for younger postmenopausal women who also want symptom relief; denosumab is suggested when bisphosphonates are unsuitable. Do not stop denosumab without a plan, because rebound vertebral fractures can occur.
Obesity questions follow the Canadian adult obesity guideline, which frames obesity as a chronic disease defined by excess adiposity that impairs health, not by BMI alone. Ask permission to discuss weight, assess root causes and complications, and support behaviour change with nutrition, physical activity and psychological interventions. Pharmacotherapy is considered for people with a BMI of 30 or more, or 27 or more with weight-related complications. Bariatric surgery is considered for a BMI of 40 or more, or 35 or more with at least one obesity-related disease. Avoid stigmatising language in counselling stems.
- Hypercalcemia: PTH first; suppressed PTH means look for malignancy
- Severe hypercalcemia: IV saline, then IV bisphosphonate
- Fragility fracture of hip or spine: treat, do not just repeat BMD
- Obesity: ask permission, assess causes and complications, then agree on a plan
Endocrine lab patterns and pitfalls
A low TSH with a low free T4 is not hyperthyroidism. It suggests central (pituitary or hypothalamic) hypothyroidism or non-thyroidal illness in a sick inpatient, so look at the other pituitary axes and the clinical setting before treating. In central hypothyroidism, follow free T4, not TSH, to adjust levothyroxine. Subclinical hypothyroidism (high TSH, normal free T4) is often just monitored with a repeat test, unless the TSH is markedly raised, the patient is pregnant or planning pregnancy, or there are clear symptoms.
Drugs change thyroid tests. Amiodarone can cause both hypothyroidism and hyperthyroidism. Lithium causes hypothyroidism and sometimes hypercalcemia. High-dose biotin supplements interfere with some laboratory immunoassays and can produce results that look like hyperthyroidism; ask about supplements when the labs do not fit the patient.
The A1C is unreliable when red cell lifespan is changed. Iron deficiency can raise it; hemolysis, recent blood loss, transfusion and some hemoglobin variants can lower or distort it. Advanced kidney disease and pregnancy also affect it. When the A1C disagrees with glucose readings, trust the glucose measurements and use fasting or 2-hour glucose for diagnosis.
Hyponatremia sits between endocrinology and nephrology. In a euvolemic patient with low serum osmolality and an inappropriately concentrated urine, SIADH is a diagnosis of exclusion: hypothyroidism and adrenal insufficiency must be ruled out first. Hyponatremia with hyperkalemia and hypotension points to primary adrenal insufficiency. Correct chronic hyponatremia slowly, because rapid correction can cause osmotic demyelination.
For calcium, correct total calcium for a low albumin, or measure ionized calcium. Check vitamin D and creatinine in any calcium workup. A high PTH with a low calcium suggests vitamin D deficiency or kidney disease (secondary hyperparathyroidism), not primary hyperparathyroidism.
- Low TSH plus low free T4: central hypothyroidism or sick euthyroid, not hyperthyroidism
- Ask about biotin, amiodarone and lithium when thyroid labs do not fit
- Anemia, hemolysis, transfusion and CKD can distort the A1C
- SIADH only after excluding hypothyroidism and adrenal insufficiency
- High PTH with low calcium: secondary hyperparathyroidism
Endocrine problems in pregnancy and planning pregnancy
Diabetes Canada recommends screening all pregnant people without known diabetes for gestational diabetes between 24 and 28 weeks of gestation, with earlier testing in those at high risk. The preferred approach starts with a 50 g glucose challenge test, followed by a 75 g oral glucose tolerance test when the result is abnormal. Management starts with nutrition therapy and activity, and insulin is the usual drug when targets are not met. After delivery, people with gestational diabetes need a 75 g oral glucose tolerance test in the months after birth and periodic screening afterwards, because their lifetime risk of type 2 diabetes is high.
People with pre-existing diabetes who plan pregnancy need preconception care: optimise glycemic control before conception, start folic acid, review medications (stop ACE inhibitors, ARBs and statins before or as soon as pregnancy is confirmed), and screen for retinopathy and kidney disease. Many non-insulin agents are switched to insulin.
Thyroid questions in pregnancy test three points. A woman on levothyroxine usually needs a higher dose as soon as pregnancy is confirmed, with TSH checked regularly. Propylthiouracil is preferred over methimazole in the first trimester because of methimazole's link to birth defects, with a switch considered later because of propylthiouracil's liver toxicity. Postpartum thyroiditis can cause a brief hyperthyroid phase followed by a hypothyroid phase, and beta-blockers, not antithyroid drugs, are used for symptoms in the first phase.
- Gestational diabetes screening: 24 to 28 weeks, earlier if high risk
- After gestational diabetes: postpartum 75 g OGTT, then ongoing screening
- Preconception: optimise A1C, folic acid, stop ACE inhibitors, ARBs and statins
- On levothyroxine and pregnant: increase dose and check TSH
Canadian practice points that differ from US sources
US resources often use different units, cut-offs and screening ages. On the MCCQE, use SI units and the Canadian guideline in the stem's context. If a stem names a guideline body, that is a strong hint which framework the examiner wants.
Coverage matters in Canadian counselling stems. Drug plans differ by province and many patients have private plans or none, so a reasonable answer may include discussing cost and coverage, or choosing an effective covered option, rather than assuming every drug is available.
- Glucose in mmol/L: 7.0 fasting and 11.1 random or 2-hour are the diagnostic cut-offs
- Driving: test glucose before driving on insulin or secretagogues; do not drive below 5.0 mmol/L
- Primary aldosteronism screening triggers come from Hypertension Canada
- Osteoporosis assessment ages come from Osteoporosis Canada, with FRAX used for risk
- Provincial drug coverage can shape which agent is chosen
How the MCCQE frames endocrine topics: three mini cases
Case one. A 54-year-old woman with type 2 diabetes on metformin and empagliflozin presents two days after laparoscopic cholecystectomy with nausea and rapid breathing. Her glucose is 11.2 mmol/L, bicarbonate is low and the anion gap is high. The options include reassurance, an antiemetic, a CT of the abdomen and a ketone level with a blood gas. The examiner is testing euglycemic DKA. Check ketones, stop the SGLT2 inhibitor and treat as DKA with fluids, insulin and dextrose.
Case two. A 76-year-old man has a TSH of 6.2 mU/L with a normal free T4 on a routine test. He feels well. The options include starting levothyroxine, thyroid ultrasound, antibodies and a repeat TSH with free T4 in a few months. The examiner is testing restraint: mild subclinical hypothyroidism in an older adult is usually monitored, and the first step is to repeat the test, because many abnormal results normalise.
Case three. A 67-year-old woman has a corrected calcium of 2.85 mmol/L found on routine bloodwork. She has mild fatigue. PTH is high-normal. The examiner wants you to recognise that an inappropriately normal PTH in hypercalcemia still means primary hyperparathyroidism. The next steps are to check vitamin D, creatinine and urine calcium, assess bone density and kidney stones, and refer for surgical assessment when criteria are met.
- SGLT2 inhibitor plus acidosis with modest glucose: euglycemic DKA
- Mild subclinical hypothyroidism: repeat before treating
- High calcium with a normal PTH: still primary hyperparathyroidism
Communication, ethics and NAC stations in endocrinology
Endocrinology produces many counselling tasks. A new diagnosis of type 2 diabetes, starting insulin, sick-day rules, hypoglycemia and driving, and an osteoporosis diagnosis after a fracture all appear in both MCQs and NAC Examination stations. The marking rewards finding out what the patient already knows, giving information in small chunks, checking understanding and agreeing on a plan.
Driving is the ethics question that recurs. A patient with severe hypoglycemia at the wheel, or with hypoglycemia unawareness, may be unfit to drive. Physicians must know their province's rules: in some provinces reporting is mandatory and in others it is discretionary. The expected answer is to tell the patient they should not drive, explain your duty, report when required and document. Do not promise confidentiality you cannot keep.
In NAC history stations, a focused endocrine history covers symptoms of the suspected condition (heat or cold intolerance, weight change, polyuria and polydipsia), complications, medications, family history and the effect on daily life. In management stations, examiners may ask at the 8-minute signal which test you would order next or which drug you would add. Answer with one choice and a short reason tied to the patient in the room.
- Start counselling by asking what the patient already knows
- Hypoglycemia and driving: advise, report if required by the province, document
- Oral questions: one clear answer plus a patient-specific reason
How to read MCCQE endocrinology stems
Read the lab table before the story. Circle the abnormal values and ask what single process explains them: high glucose with a low bicarbonate and a high anion gap is DKA; low sodium with high potassium and hypotension is adrenal insufficiency; high calcium with low PTH is malignancy until proven otherwise.
Then look for the cue that changes the next step. A low potassium in DKA means potassium before insulin. An SGLT2 inhibitor in the medication list means euglycemic DKA. A low TSH in a nodule stem means scan before biopsy. Long-term prednisone in a hypotensive patient means adrenal crisis. Known cardiovascular disease, heart failure or CKD in a diabetes stem means add a cardiorenal agent.
Finally, watch for over-investigation. The MCCQE rewards ordering the one test that changes management. Repeating an abnormal test is right when confirmation is needed (a second diagnostic glucose), but wrong when the result already demands action.
- Low potassium in DKA: replace before insulin
- Medication list: SGLT2 inhibitor, steroids, lithium, amiodarone, thiazides
- Unstable patient: treat first (hydrocortisone, glucose, fluids), confirm later
One-week endocrinology revision plan
- Day 1Diabetes diagnosis and drugsDiabetes Canada cut-offs, A1C targets and the drug-choice approach, including cardiorenal agents.
- Day 2Diabetic emergenciesWrite the DKA and HHS sequences from memory; hypoglycemia, unawareness and driving.
- Day 3ThyroidTSH-first testing, uptake scans, nodules, thyroiditis, lab pitfalls and pregnancy.
- Day 4Adrenal and pituitaryAdrenal crisis, Cushing, aldosteronism, pheochromocytoma, prolactin and apoplexy.
- Day 5Calcium, bone and obesityPTH-based calcium workup, Osteoporosis Canada assessment and treatment, obesity guideline.
- Day 6Mixed timed blocksLab-heavy endocrine questions; write down the one cue that decided each answer.
- Day 7Review and counsellingRedo missed questions and rehearse sick-day, insulin and driving counselling aloud.
| Presentation | Key finding | First step | Canadian practice pearl |
|---|---|---|---|
| New type 2 diabetes | A1C 1.5% or more above target | Metformin plus a second agent | Diabetes Canada individualises the A1C target |
| Type 2 diabetes with ASCVD, HF or CKD | Known cardiorenal disease | Add SGLT2 inhibitor or GLP-1 RA with proven benefit | Added regardless of A1C |
| DKA | High anion gap, ketones, low potassium | Fluids, replace potassium, then insulin | Stop insulin only when the gap closes |
| Hypoglycemia on insulin | Glucose below 4.0 mmol/L | 15 g fast-acting carbohydrate, recheck | No driving below 5.0 mmol/L |
| Hyperthyroidism | Low TSH, high free T4 | Radionuclide uptake scan for cause | Thyroiditis needs supportive care only |
| Thyroid nodule | Low TSH | Radionuclide scan before biopsy | TSH and ultrasound start the workup |
| Adrenal crisis | Hypotension, low sodium, high potassium | IV hydrocortisone and fluids now | Do not wait for cortisol results |
| Hypercalcemia | High calcium, low PTH | Look for malignancy; IV saline if severe | Bisphosphonate after rehydration |
| Osteoporosis assessment | Age 70 or older, or risk factors | FRAX and BMD | Bisphosphonate first-line |
Worked examples in MCCQE style
Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for endocrinology.
Example 1
A 19-year-old woman with type 1 diabetes presents with 2 days of vomiting and abdominal pain. HR 122/min, BP 98/60 mm Hg. Glucose 27.6 mmol/L, sodium 133 mmol/L, potassium 3.0 mmol/L, bicarbonate 8 mmol/L, anion gap 25, venous pH 7.10, serum ketones high. One litre of 0.9% sodium chloride has been given.
What is the most appropriate next step?
-
Insulin shifts potassium into cells and can cause life-threatening hypokalemia when potassium is already low.
-
Bicarbonate is reserved for very severe acidosis and does not fix the potassium problem.
-
With low potassium, replace it first and delay insulin until the level is safe, while continuing fluids.
-
Subcutaneous insulin is unreliable in shock and still lowers potassium.
-
Dextrose is added when glucose falls during treatment, not at a glucose of 27.6 mmol/L.
Show answer and reasoning
Answer: C. Give IV potassium and hold insulin for now
- A. Insulin shifts potassium into cells and can cause life-threatening hypokalemia when potassium is already low.
- B. Bicarbonate is reserved for very severe acidosis and does not fix the potassium problem.
- C. With low potassium, replace it first and delay insulin until the level is safe, while continuing fluids.
- D. Subcutaneous insulin is unreliable in shock and still lowers potassium.
- E. Dextrose is added when glucose falls during treatment, not at a glucose of 27.6 mmol/L.
In DKA, give fluids, then check potassium: if it is low, replace it before starting insulin.
Based on: Diabetes Canada Clinical Practice Guidelines: hyperglycemic emergencies in adults
Example 2
A 63-year-old man with type 2 diabetes had a myocardial infarction 1 year ago. He takes metformin at the maximum tolerated dose, atorvastatin, ramipril and ASA. A1C is 7.6%. eGFR is 64 mL/min/1.73 m2, and his BMI is 31 kg/m2. He has no history of pancreatitis or genital infections.
What is the most appropriate change to his diabetes therapy?
-
A sulfonylurea lowers A1C but has no proven cardiovascular benefit and causes hypoglycemia and weight gain.
-
DPP-4 inhibitors are cardiovascular neutral, so they miss the benefit he needs.
-
Insulin is not needed for a modest A1C rise without decompensation.
-
Established ASCVD calls for a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit; his weight favours a GLP-1 receptor agonist.
-
Pioglitazone causes fluid retention and weight gain and is not the preferred cardiorenal choice.
Show answer and reasoning
Answer: D. Add a GLP-1 RA with proven CV benefit
- A. A sulfonylurea lowers A1C but has no proven cardiovascular benefit and causes hypoglycemia and weight gain.
- B. DPP-4 inhibitors are cardiovascular neutral, so they miss the benefit he needs.
- C. Insulin is not needed for a modest A1C rise without decompensation.
- D. Established ASCVD calls for a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit; his weight favours a GLP-1 receptor agonist.
- E. Pioglitazone causes fluid retention and weight gain and is not the preferred cardiorenal choice.
In type 2 diabetes with ASCVD, add an agent with proven cardiovascular benefit, whatever the A1C.
Based on: Diabetes Canada Clinical Practice Guidelines: pharmacologic glycemic management of type 2 diabetes in adults
Example 3
A 44-year-old woman notices a lump in her neck. She reports palpitations and weight loss of 3 kg. Examination shows a 2.5 cm firm nodule in the left lobe without lymphadenopathy. TSH is 0.02 mU/L and free T4 is mildly raised. Ultrasound confirms a solitary solid nodule.
What is the most appropriate next investigation?
-
With a suppressed TSH, the nodule may be autonomous (hot) and rarely malignant, so scan before biopsy.
-
A low TSH with a nodule calls for a radionuclide scan; a hot nodule usually does not need aspiration.
-
Iodinated contrast can worsen hyperthyroidism and interferes with later radioiodine therapy.
-
Thyroglobulin is not a diagnostic test for a nodule, and calcitonin is not routine here.
-
She has hyperthyroidism and a significant nodule, so waiting a year is unsafe.
Show answer and reasoning
Answer: B. Radionuclide thyroid scan and uptake
- A. With a suppressed TSH, the nodule may be autonomous (hot) and rarely malignant, so scan before biopsy.
- B. A low TSH with a nodule calls for a radionuclide scan; a hot nodule usually does not need aspiration.
- C. Iodinated contrast can worsen hyperthyroidism and interferes with later radioiodine therapy.
- D. Thyroglobulin is not a diagnostic test for a nodule, and calcitonin is not routine here.
- E. She has hyperthyroidism and a significant nodule, so waiting a year is unsafe.
Thyroid nodule plus low TSH: radionuclide scan first. Normal or high TSH: ultrasound features decide on aspiration.
Based on: Canadian endocrine practice for thyroid nodules; American Thyroid Association nodule guideline
Example 4
A 58-year-old woman took prednisone 20 mg daily for 8 months for polymyalgia rheumatica and stopped it on her own 10 days ago. She presents with vomiting and dizziness. Blood pressure is 78/44 mmHg after 2 L of 0.9% sodium chloride. Sodium is 128 mmol/L, potassium 5.0 mmol/L and glucose 3.6 mmol/L.
What is the most appropriate next step?
-
Correct. Suspected adrenal crisis with shock needs IV hydrocortisone and fluids immediately; a cortisol sample can be drawn if it does not delay treatment.
-
Confirmatory testing can wait until she is stable; delaying steroids in crisis can be fatal.
-
Mineralocorticoid replacement alone is too slow and does not replace the missing glucocorticoid.
-
Imaging does not change immediate management, and suppression from stopping steroids is the likely cause.
-
Oral steroids are unreliable while she is vomiting and in shock.
Show answer and reasoning
Answer: A. IV hydrocortisone now, before test results
- A. Correct. Suspected adrenal crisis with shock needs IV hydrocortisone and fluids immediately; a cortisol sample can be drawn if it does not delay treatment.
- B. Confirmatory testing can wait until she is stable; delaying steroids in crisis can be fatal.
- C. Mineralocorticoid replacement alone is too slow and does not replace the missing glucocorticoid.
- D. Imaging does not change immediate management, and suppression from stopping steroids is the likely cause.
- E. Oral steroids are unreliable while she is vomiting and in shock.
Hypotension after stopping long-term steroids is adrenal crisis until proven otherwise: IV hydrocortisone first.
Based on: Canadian endocrine practice for adrenal insufficiency; Endocrine Society adrenal insufficiency guideline
Example 5
A 72-year-old woman had surgical repair of a hip fracture after tripping on a rug at home 6 weeks ago. She has no other fractures. eGFR is 58 mL/min/1.73 m2, calcium and 25-hydroxyvitamin D are normal, and she has no dental problems. She asks what can be done to prevent another fracture.
What is the most appropriate management?
-
BMD can still be measured, but a hip fragility fracture is itself an indication for treatment and testing should not delay it.
-
Calcium and vitamin D support bone health but do not reduce fracture risk enough after a hip fracture.
-
Calcitonin is not a first-line osteoporosis therapy.
-
Waiting two years leaves a very high-risk patient untreated.
-
Correct. After a hip fragility fracture, Osteoporosis Canada supports starting treatment, and bisphosphonates are first-line with adequate kidney function.
Show answer and reasoning
Answer: E. Start bisphosphonate therapy now
- A. BMD can still be measured, but a hip fragility fracture is itself an indication for treatment and testing should not delay it.
- B. Calcium and vitamin D support bone health but do not reduce fracture risk enough after a hip fracture.
- C. Calcitonin is not a first-line osteoporosis therapy.
- D. Waiting two years leaves a very high-risk patient untreated.
- E. Correct. After a hip fragility fracture, Osteoporosis Canada supports starting treatment, and bisphosphonates are first-line with adequate kidney function.
A hip or vertebral fragility fracture is an indication to treat; do not wait for a BMD result.
Based on: Osteoporosis Canada clinical practice guideline
Quick recall
Tap a card to turn it over. If you can answer all of them without looking, move on to timed questions.
Where candidates lose marks
- Insulin before potassium
Starting insulin with a low potassium in DKA can trigger fatal arrhythmia. Replace potassium first.
- Ordering a full thyroid panel
TSH alone is the right first test; T3 and routine thyroid ultrasound are rarely needed.
- Biopsying a hot nodule
With a low TSH, scan first; autonomous nodules are rarely malignant.
- Waiting for cortisol in crisis
A hypotensive patient with suspected adrenal crisis gets hydrocortisone now.
- Choosing glucose-only drugs
In ASCVD, heart failure or CKD, the expected answer adds an agent with proven cardiorenal benefit.
How to study endocrinology
Memorise Diabetes Canada diagnostic cut-offs, A1C targets and the drug-choice algorithm.
Write out the DKA and HHS treatment sequence from memory until it is automatic.
Practise reading thyroid panels and uptake scan results with short timed drills.
Review adrenal crisis, Cushing, aldosteronism and pheochromocytoma screening as one set.
Learn the calcium workup and Osteoporosis Canada assessment ages and first-line drugs.
Finish with mixed timed blocks of endocrine questions and review every distractor.
Sources and further reading
Check the current edition of each guideline before your exam. This page is study material, not clinical advice.
- Medical Council of Canada: MCCQE and Examination Objectives
- Diabetes Canada Clinical Practice Guidelines
- Osteoporosis Canada: clinical practice guideline
- Hypertension Canada guidelines
- Obesity Canada: Canadian Adult Obesity Clinical Practice Guidelines
- Choosing Wisely Canada: endocrinology and metabolism recommendations